新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Clinical Nutrition:克罗恩病的新疗法

Clinical Nutrition:克罗恩病的新疗法

来源:生物谷 2012-03-22 13:09

最近,弗吉尼亚工学院营养免疫学与分子医学实验室(NIMML)的研究团队报道了关于克罗恩病治疗的重要新信息,即共轭亚油酸(CLA,conjugated linoleic acid)具有治疗克罗恩病的功效。

克罗恩病是一种炎性肠病(IBD,inflammatory bowel disease),主要有两种表现,即克罗恩病和溃疡性结肠炎,它折磨着140多万美国人。症状包括腹绞痛、发烧、疲乏、厌食、皮肤口腔溃疡和腹泻或便秘。此外,在IBD患者中,发展结直肠癌的风险每年约增加1%。当前,克罗恩病没有治愈方法,也不了解此病的确切原因。研究人员发现,平时补充共轭亚油酸的克罗恩病患者表现出明显的好转。最近一项CLA研究表明,轻度至中度克罗恩病患者补充CLA后,50%患者的生活质量得到明显改善。

共轭亚油酸具有抗癌和免疫调节特性,是牛奶和反刍动物产品中的一种天然脂肪酸,可由益生菌(probiotic bacteria)产生,能抑制肠炎,为轻度至中度IBD患者提供了一种有效的治疗方法,而且没有许多合成药物的不必要副作用。

关于此研究的文章将于近期发表在期刊Clinical Nutrition上。(生物谷bioon.com)

Novel Therapy Discovered for Crohn's Disease

sciencedaily/Mar. 19, 2012

The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties.

In collaboration with the Division of Gastroenterology and Hepathology at University of North Carolina School of Medicine and the Wake Forest Medical Center, researchers found that Crohn's patients who took supplementary CLA showed noticeable improvement. "In our recent open label study of CLA as a supplement in study subjects with mild to moderate CD there was a marked improvement in disease activity and quality of life in 50% of the subjects. CLA was well tolerated by all of the study subjects. These findings are very encouraging and will need to be verified in a randomized controlled trial," said Professor Kim L. Isaacs, a Professor of Gastroenterology at the University of North Carolina at Chapel Hill.

The two main manifestations of IBD -- Crohn's and ulcerative colitis -- afflict over 1.4 million people in the United States. Symptoms include abdominal cramping, fever, fatigue, loss of appetite, skin and mouth ulcers, and diarrhea or constipation. In addition, the risk of developing colorectal cancer increases by about one percent yearly in IBD patients. Currently, there is no cure for Crohn's disease and the exact causes of it aren't fully understood.

CLA affords those afflicted with mild to moderate IBD an effective treatment without the unwanted side effects of many synthetic drugs. "Furthermore, we have demonstrated that probiotic bacteria can produce CLA locally and suppress colitis. Therefore, CLA can be administered directly in capsules or indirectly through CLA-producing probiotic bacteria," said Dr. Raquel Hontecillas, an Assistant Professor of Immunology at NIMML.

NIMML strives to develop safer and more effective therapies for human chronic inflammatory diseases from Nature's own medicine cabinet. To achieve this, NIMML uses advanced computational modeling in addition to mechanistic and clinical experimentation. "The validation of the anti-inflammatory actions of CLA in the gut is in line with our goal because CLA is a natural fatty acid found in milk and

ruminant products. The fully integrated bioinformatics, nutrition and immunology experimentation capabilities of NIMML enable the acceleration of translational biomedical research from computational and mathematical modeling into the clinic. CLA is an example of an anti-inflammatory compound in a pipeline of naturally occurring and synthetic compounds (e.g., abscisic acid, eleostearic acid, terephthalanilides) with tremendous therapeutic and prophylactic potential as anti-inflammatories," said Dr. Josep Bassaganya-Riera, a Professor of Immunology, principal investigator of this human clinical trial, and the Director of the NIMML and the Center for Modeling Immunity to Enteric Pathogens.

These findings, reported in the most recent edition of Clinical Nutrition, were awarded the American College of Gastroenterology Presidential Poster of distinction for human clinical trials.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库